Drug Profile
Ustekinumab - Janssen Biotech
Alternative Names: Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara; Stellara; Sterrara; SuteraraLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Centocor; Medarex
- Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Ulcerative colitis
- Phase III Dermatomyositis; Polymyositis; Spondylarthritis; Vasculitis
- Phase II Atopic dermatitis
- Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus
Most Recent Events
- 26 Jan 2024 Janssen Biotech completes a phase I trial in Psoriasis (In adolescents, In children, In infants) in USA (SC) (NCT05252533)
- 02 Jan 2024 Phase-III clinical trials in Psoriatic arthritis (In adolescents, In children) in Argentina, Denmark, Germany, Italy, Spain, Turkey, United Kingdom (SC) (NCT05083182) (EudraCT2020-005503-40)
- 02 Jan 2024 Janssen Research & Development initiates a Phase-III clinical trials in Psoriatic arthritis (In adolescents, In children) in France and Poland (SC) (NCT05083182) (EudraCT2020-005503-40)